Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	435.83	233.18	145.24	109.46	131.84	198.32
Revenue Growth (YoY)	114.22%	60.55%	32.69%	-16.97%	-33.52%	13.11%
Cost of Revenue	220.55	225.24	256.44	231.75	204.98	137.9
Gross Profit	215.28	7.94	-111.2	-122.29	-73.14	60.42
Selling, General & Admin	305.01	264.12	265.54	197.52	126.28	135.8
Operating Expenses	305.01	264.12	265.54	197.52	126.28	135.8
Operating Income	-89.73	-256.18	-376.74	-319.81	-199.43	-75.38
Interest Expense	-11.27	-11.18	-11.33	-11.01	-19.68	-19.05
Interest & Investment Income	13.92	17.82	21.77	6.28	1.99	5
Earnings From Equity Investments	-	-3.4	-	-	-	-
Currency Exchange Gain (Loss)	-0.7	-0.7	0.5	1.4	0.3	1.2
Other Non Operating Income (Expenses)	0.63	0.78	1.09	-0.43	-0.07	0.22
EBT Excluding Unusual Items	-87.15	-252.87	-364.72	-323.58	-216.88	-88
Merger & Restructuring Charges	-1.4	-2.44	-11.39	-	-	-
Other Unusual Items	-	-	-	-7.58	-	-3.66
Pretax Income	-88.55	-320.51	-376.11	-331.16	-216.88	-188.79
Income Tax Expense	-0.01	0.12	0.22	0.31	0.41	-19.36
Earnings From Continuing Operations	-88.54	-320.63	-376.33	-331.47	-217.29	-169.43
Earnings From Discontinued Operations	0	-0.92	264.93	52.99	37.2	-
Net Income	-88.54	-321.55	-111.4	-278.48	-180.09	-169.43
Net Income to Common	-88.54	-321.55	-111.4	-278.48	-180.09	-169.43
Shares Outstanding (Basic)	87	79	74	64	60	48
Shares Outstanding (Diluted)	87	79	74	64	60	48
Shares Change (YoY)	13.19%	6.22%	16.48%	6.56%	25.86%	12.28%
EPS (Basic)	-1.01	-4.08	-1.50	-4.37	-3.01	-3.56
EPS (Diluted)	-1.02	-4.08	-1.50	-4.37	-3.01	-3.56
Free Cash Flow	-58.91	-237.48	-280.02	-186.29	-19.89	-49.51
Free Cash Flow Per Share	-0.67	-3.01	-3.77	-2.92	-0.33	-1.04
Gross Margin	49.40%	3.40%	-76.57%	-111.72%	-55.48%	30.47%
Operating Margin	-20.59%	-109.87%	-259.40%	-292.17%	-151.27%	-38.01%
Profit Margin	-20.32%	-137.90%	-76.70%	-254.41%	-136.60%	-85.43%
Free Cash Flow Margin	-13.52%	-101.84%	-192.80%	-170.19%	-15.09%	-24.96%
EBITDA	-35.03	-212.63	-338.21	-299.09	-186.68	-50.8
EBITDA Margin	-8.04%	-91.19%	-232.87%	-273.25%	-141.60%	-25.61%
D&A For EBITDA	54.7	43.56	38.53	20.72	12.75	24.58
EBIT	-89.73	-256.18	-376.74	-319.81	-199.43	-75.38
EBIT Margin	-20.59%	-109.87%	-259.40%	-292.17%	-151.27%	-38.01%
Revenue as Reported	435.83	233.18	145.24	109.46	131.84	198.32

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q